FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3047150555> ?p ?o ?g. }

• W3047150555 endingPage "658" @default.
• W3047150555 startingPage "657.1" @default.
• W3047150555 abstract "Background: Comorbidities in rheumatic diseases (RDs) have been associated with increased morbidity and mortality. Evidence on prevalence of comorbidities in antiphospholipid syndrome (APS) and its difference from high comorbidity burden RDs is limited. Objectives: To compare the prevalence of common comorbidities between APS [primary (PAPS) and Systemic lupus erythematosus (SLE)-APS] and Rheumatoid arthritis (RA) patients. Methods: 326 APS patients from the Greek registry (237 women, mean age 48.7±13.4 years, 161 PAPS) were matched 1:2 for age and sex with 652 RA patients from Greek RA Registry. Prevalence of cardiovascular (CV) risk factors, stroke, coronary artery disease (CAD), osteoporosis, diabetes mellitus (DM), Chronic obstructive pulmonary disease (COPD), depression and neoplasms were compared between APS and RA using logistic regression analysis. Results: Regarding CV burden, hyperlipidemia and obesity (ΒMI≥30) were comparable while hypertension, smoking, CAD and stroke were more prevalent in APS compared to RA patients (Table 1). Osteoporosis and depression were more frequent in APS while DM, COPD and neoplasms were comparable between two groups. Comparison of APS subgroups to 1:2 matched RA patients revealed that smoking and stroke were more prevalent in PAPS and SLE-APS vs RA. Hypertension, CAD and osteoporosis were more prevalent only in SLE-APS vs. RA while DM was less prevalent in PAPS vs. RA patients. Table 1. Comparison of comorbidities between Antiphospholipid syndrome (APS) vs. matched Rheumatoid Arthritis (RA) patients and between primary APS (PAPS) or Systemic Lupus Erythematosus-APS (SLE-APS) vs matched RA patients APS RA OR* PAPS RA OR SLE-APS RA OR n (%) 326 652 161 322 165 330 Hypertension 97 (29.8) 136 (21) 1.61 (1.19-2.18) 40 (25) 75 (23.3) 1.09 (0.70-1.69) 57 (34.6) 61 (18.5) 2.33 (1.52-3.56) Smoking 175 (53.7) 264 (40.5) 1.70 (1.30-2.22) 87 (54) 142 (44) 1.49 (1.02-2.18) 88 (53.3) 122 (37) 1.95 (1.33-2.85) Hyperlipidemia 79 (24.2) 135 (20.7) 1.23 (0.89-1.68) 40 (24.8) 62 (19.3) 1.39 (0.88-2.18) 39 (23.6) 73 (22) 1.09 (0.70-1.70) Obesity 48 (20.5) 105 (19.5) 1.06 (0.73-1.56) 20 (17) 51 (19) 0.86 (0.49-1.52) 28 (24) 54 (19.7) 1.28 (0.76-2.15) Stroke ± 66 (20.3) 9 (1.4) 13.8 (6.5-29.1) 36 (22.4) 4 (1.2) 19.9 (6.6-59.9) 30 (18.2) 5 (1.5) 7.8 (2.7-22.6) Coronary disease ± 16 (4.9) 13 (2) 3.14 (1.17-8.45) 2 (1.2) 7 (2.2) 0.46 (0.04-4.77) 14 (8.5) 6 (1.8) 10.9 (2.7-44.3) Osteoporosis × 66 (20.3) 92 (14) 1.45 (1.01-2.06) 19 (11.8) 42 (13) 0.96 (0.54-1.73) 47 (28.5) 50 (15) 1.91 (1.20-3.05) Diabetes × 18 (5.5) 58 (9) 0.58 (0.33-1.01) 5 (3) 29 (9) 0.34 (0.13-0.89) 13 (8) 29 (9) 0.88 (0.44-1.79) COPD ≠ 11 (3.4) 14 (2.2) 1.26 (0.56-2.84) 3 (1.9) 6 (2) 0.96 (0.23-4.0) 8 (5) 8 (2.4) 1.28 (0.44-3.72) Depression # 53 (16.3) 66 (10) 1.70 (1.15-2.53) 23 (14) 30 (9.3) 1.69 (0.93-3.05) 30 (18.2) 36 (10.9) 1.65 (0.96-2.84) Neoplasms ˅ 14 (4.3) 27 (4.1) 1.05 (0.54-2.06) 5 (3) 12 (3.7) 0.84 (0.28-2.52) 9 (5.5) 15 (4.6) 1.31 (0.55-3.1) * OR: Odds ratio, crude or adjusted for: ± age, sex, smoking, hypertension, hyperlipidemia, BMI, corticosteroid (Cs) duration × Cs duration ≠ smoking, Cs duration # sex, disease duration, Cs duration ˅ age, disease duration Conclusion: Comorbidity burden in APS (PAPS and SLE-APS) is comparable or even higher to that in RA, entailing a high level of diligence for CV risk prevention, awareness for depression and corticosteroid exposure minimization. Disclosure of Interests: Stylianos Panopoulos: None declared, Konstantinos Thomas: None declared, Georgios Georgiopoulos: None declared, Dimitrios Boumpas Grant/research support from: Unrestricted grant support from various pharmaceutical companies, Christina Katsiari: None declared, George Bertsias Grant/research support from: GSK, Consultant of: Novartis, Alexandros Drosos: None declared, Kyriaki Boki: None declared, Theodoros Dimitroulas: None declared, Alexandros Garyfallos Grant/research support from: MSD, Aenorasis SA, Speakers bureau: MSD, Novartis, gsk, Charalambos Papagoras: None declared, PELAGIA KATSIMPRI: None declared, Apostolos Tziortziotis: None declared, Christina Adamichou: None declared, Evripidis Kaltsonoudis: None declared, Evangelia Argyriou: None declared, GEORGIOS VOSVOTEKAS Grant/research support from: MSD, Janssen, Consultant of: MSD, Novartis, Roche, UCB pharma, Bristol-Myers Squibb, AbbVie, Speakers bureau: UCB pharma, Menarini, Bristol-Myers Squibb, MSD, Petros Sfikakis Grant/research support from: Grant/research support from Abvie, Novartis, MSD, Actelion, Amgen, Pfizer, Janssen Pharmaceutical, UCB, Dimitrios Vassilopoulos: None declared, Maria Tektonidou Grant/research support from: AbbVie, MSD, Novartis and Pfizer, Consultant of: AbbVie, MSD, Novartis and Pfizer" @default.
• W3047150555 created "2020-08-10" @default.
• W3047150555 creator A5002000717 @default.
• W3047150555 creator A5003124517 @default.
• W3047150555 creator A5007341235 @default.
• W3047150555 creator A5009683593 @default.
• W3047150555 creator A5022957883 @default.
• W3047150555 creator A5027669920 @default.
• W3047150555 creator A5031697676 @default.
• W3047150555 creator A5034748610 @default.
• W3047150555 creator A5039759199 @default.
• W3047150555 creator A5048007142 @default.
• W3047150555 creator A5052648432 @default.
• W3047150555 creator A5057662972 @default.
• W3047150555 creator A5058879534 @default.
• W3047150555 creator A5069455566 @default.
• W3047150555 creator A5070206045 @default.
• W3047150555 creator A5074848555 @default.
• W3047150555 creator A5074911675 @default.
• W3047150555 creator A5075199538 @default.
• W3047150555 creator A5075515457 @default.
• W3047150555 creator A5086939776 @default.
• W3047150555 date "2020-06-01" @default.
• W3047150555 modified "2023-09-27" @default.
• W3047150555 title "FRI0147 PREVALENCE OF COMORBIDITIES IN ANTIPHOSPHOLIPID SYNDROME VERSUS RHEUMATOID ARTHRITIS: A MULTICENTRE, AGE- AND SEX-MATCHED STUDY" @default.
• W3047150555 doi "https://doi.org/10.1136/annrheumdis-2020-eular.1883" @default.
• W3047150555 hasPublicationYear "2020" @default.
• W3047150555 type Work @default.
• W3047150555 sameAs 3047150555 @default.
• W3047150555 citedByCount "0" @default.
• W3047150555 crossrefType "journal-article" @default.
• W3047150555 hasAuthorship W3047150555A5002000717 @default.
• W3047150555 hasAuthorship W3047150555A5003124517 @default.
• W3047150555 hasAuthorship W3047150555A5007341235 @default.
• W3047150555 hasAuthorship W3047150555A5009683593 @default.
• W3047150555 hasAuthorship W3047150555A5022957883 @default.
• W3047150555 hasAuthorship W3047150555A5027669920 @default.
• W3047150555 hasAuthorship W3047150555A5031697676 @default.
• W3047150555 hasAuthorship W3047150555A5034748610 @default.
• W3047150555 hasAuthorship W3047150555A5039759199 @default.
• W3047150555 hasAuthorship W3047150555A5048007142 @default.
• W3047150555 hasAuthorship W3047150555A5052648432 @default.
• W3047150555 hasAuthorship W3047150555A5057662972 @default.
• W3047150555 hasAuthorship W3047150555A5058879534 @default.
• W3047150555 hasAuthorship W3047150555A5069455566 @default.
• W3047150555 hasAuthorship W3047150555A5070206045 @default.
• W3047150555 hasAuthorship W3047150555A5074848555 @default.
• W3047150555 hasAuthorship W3047150555A5074911675 @default.
• W3047150555 hasAuthorship W3047150555A5075199538 @default.
• W3047150555 hasAuthorship W3047150555A5075515457 @default.
• W3047150555 hasAuthorship W3047150555A5086939776 @default.
• W3047150555 hasBestOaLocation W30471505551 @default.
• W3047150555 hasConcept C126322002 @default.
• W3047150555 hasConcept C127413603 @default.
• W3047150555 hasConcept C134018914 @default.
• W3047150555 hasConcept C139719470 @default.
• W3047150555 hasConcept C162324750 @default.
• W3047150555 hasConcept C2776541429 @default.
• W3047150555 hasConcept C2776780178 @default.
• W3047150555 hasConcept C2776867660 @default.
• W3047150555 hasConcept C2776874634 @default.
• W3047150555 hasConcept C2777575956 @default.
• W3047150555 hasConcept C2779159551 @default.
• W3047150555 hasConcept C2780645631 @default.
• W3047150555 hasConcept C2780868729 @default.
• W3047150555 hasConcept C555293320 @default.
• W3047150555 hasConcept C71924100 @default.
• W3047150555 hasConcept C78519656 @default.
• W3047150555 hasConceptScore W3047150555C126322002 @default.
• W3047150555 hasConceptScore W3047150555C127413603 @default.
• W3047150555 hasConceptScore W3047150555C134018914 @default.
• W3047150555 hasConceptScore W3047150555C139719470 @default.
• W3047150555 hasConceptScore W3047150555C162324750 @default.
• W3047150555 hasConceptScore W3047150555C2776541429 @default.
• W3047150555 hasConceptScore W3047150555C2776780178 @default.
• W3047150555 hasConceptScore W3047150555C2776867660 @default.
• W3047150555 hasConceptScore W3047150555C2776874634 @default.
• W3047150555 hasConceptScore W3047150555C2777575956 @default.
• W3047150555 hasConceptScore W3047150555C2779159551 @default.
• W3047150555 hasConceptScore W3047150555C2780645631 @default.
• W3047150555 hasConceptScore W3047150555C2780868729 @default.
• W3047150555 hasConceptScore W3047150555C555293320 @default.
• W3047150555 hasConceptScore W3047150555C71924100 @default.
• W3047150555 hasConceptScore W3047150555C78519656 @default.
• W3047150555 hasIssue "Suppl 1" @default.
• W3047150555 hasLocation W30471505551 @default.
• W3047150555 hasOpenAccess W3047150555 @default.
• W3047150555 hasPrimaryLocation W30471505551 @default.
• W3047150555 hasRelatedWork W1033578521 @default.
• W3047150555 hasRelatedWork W1981261777 @default.
• W3047150555 hasRelatedWork W2067958944 @default.
• W3047150555 hasRelatedWork W2114200376 @default.
• W3047150555 hasRelatedWork W2153553958 @default.
• W3047150555 hasRelatedWork W2552520857 @default.
• W3047150555 hasRelatedWork W3134859527 @default.
• W3047150555 hasRelatedWork W3207487408 @default.
• W3047150555 hasRelatedWork W4281399753 @default.
• W3047150555 hasRelatedWork W4307630664 @default.

• next